Vical Incorporated (VICL) Announces News Release and Conference Call Schedule for 2009 Financial Results
2/4/2010 8:42:21 AM
More...
|
Vical Incorporated (VICL) Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma
1/28/2010 9:57:40 AM
More...
|
Vical Incorporated (VICL) Updates Vaccine Development Programs for CMV and Pandemic Influenza
1/26/2010 8:44:54 AM
More...
|
Vical Incorporated (VICL) Names Richard T. Kenney, M.D., Vice President of Clinical Development
1/14/2010 9:23:04 AM
More...
|
Vical Incorporated (VICL) Says PAD Drug Gets Nod for Late Stage Trial
1/12/2010 6:53:36 AM
More...
|
Vical Incorporated (VICL) Secures $25 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
1/11/2010 9:30:32 AM
More...
|
Vical Incorporated (VICL) Announces Licensee's Approval of ONCEPT(TM) Therapeutic Melanoma Vaccine for Dogs
1/11/2010 9:05:42 AM
More...
|
Mechanism of Action for Vical Incorporated (VICL)'s Vaxfectin(R) Adjuvant Expands Potential Applications
1/7/2010 9:02:54 AM
More...
|
Vical Incorporated (VICL) Confirms Advantages of DNA Technology Platform With Vaccine for H1N1 Influenza
12/29/2009 10:55:42 AM
More...
|
Vical Incorporated (VICL)'s Late-Stage Trial Gets Positive Review
12/28/2009 6:43:26 AM
More...
|
|